Navigation Links
Epilepsy drug dosage linked to specific birth defects
Date:8/25/2013

In a world first, new Australian medical research has given pregnant women with epilepsy new hope of reducing their chance of having a baby with physical birth defects.

According to research published in the September 2013 issue of Neurology, the medical journal of the American Academy of Neurology, epilepsy experts at The Royal Melbourne Hospital have discovered a link between high doses of common epilepsy drug valproate and the increased risk of having a baby with spina bifida or hypospadias.

Royal Melbourne Hospital epilepsy specialist and Head of the Department of Medicine at The University of Melbourne, Professor Terry O'Brien, said there was increasing concern among clinicians, patients and their families about the risk to the developing fetus of mothers taking valproate.

"For many women on epilepsy medication, the desire to start a family can be fraught with fear that they could have a baby with a range of disabilities or malformations," Professor O'Brien said.

"Previous studies have shown a strong relationship between the dose of valproate taken and the risk of the child having a birth defect. However, for many women valproate is the only drug that will help control their seizures.

"Through our research, we now know that by reducing the dose taken in the first trimester of pregnancy, the risk of having a baby with spina bifida or hypospadias will be greatly reduced."

Spina bifida is a birth defect of the spine and spinal cord, which occurs in utero in the first three months of pregnancy and cannot be cured. Hypospadias is a birth defect of the penis but can be treated with surgery.

Professor O'Brien added other birth defects such as cleft palates and heart defects were still common irrespective of the drug dosage given to pregnant women.

The research data was extracted from the Australian Pregnancy Register (APR), based at The Royal Melbourne Hospital.

The APR
'/>"/>

Contact: Melea Tarabay
melea.tarabay@mh.org.au
61-393-427-469
Melbourne Health
Source:Eurekalert

Page: 1 2

Related biology news :

1. Evidence of familial vulnerability for epilepsy and psychosis
2. Study raises questions about use of anti-epilepsy drugs in newborns
3. New model synapse could shed light on disorders such as epilepsy and anxiety
4. University of Minnesota engineering researchers discover new non-invasive method for diagnosing epilepsy
5. All in the family: A genetic link between epilepsy and migraine
6. Cats and humans suffer from similar forms of epilepsy
7. Dysfunction in cerebellar Calcium channel causes motor disorders and epilepsy
8. Lower dosage CT-guided lung biopsy protocol maintains quality, minimizes exposure
9. AcelRx Pharmaceuticals Receives First U.S. Patent for Small-Volume Oral Transmucosal Dosage Forms
10. Optimal vitamin D dosage for infants uncertain
11. Exposure to antibiotics linked to severity of allergic asthma: UBC research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 2014) Scientists at The New York Stem ... closer to creating a viable cell replacement therapy ... , For the first time, NYSCF scientists ... skin samples of patients with primary progressive multiple ... to induce these stem cells into becoming oligodendrocytes, ...
(Date:7/24/2014)... 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced ... control Phase 3 study of Zerenex (ferric citrate), the ... treatment of hyperphosphatemia in patients with end-stage renal disease ... iRon delivery with FErric CiTrate in EsrD) was published ... Society of Nephrology ( JASN ). ...
(Date:7/24/2014)... YORK, NY (July 24, 2014) Scientists at ... Institute are one step closer to creating a ... a patient,s own cells. , For the ... (iPS) cells lines from skin samples of patients ... developed an accelerated protocol to induce these stem ...
Breaking Biology News(10 mins):NYSCF scientists one step closer to cell therapy for multiple sclerosis patients 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2
... directed by Scripps Research Professor Benjamin Cravatt, Ph.D., ... of The Journal of Biological Chemistry. , The ... previously suggested-for the biosynthesis of neurotransmitter lipids, N-acyl ... anandamide. The high activity of the enzyme a/b ...
... within the cell nucleus and performs one of the ... machines that convert the genetic information carried by messenger ... , Gary Karpen and Jamy Peng, researchers in ... Lawrence Berkeley National Laboratory, have now discovered two pathways ...
... Scripps Research Professor Benjamin Cravatt, Ph.D., is being ... Journal of Biological Chemistry. , The new study ... the biosynthesis of neurotransmitter lipids, N-acyl ethanolamines (NAEs), ... high activity of the enzyme a/b hydrolase4 (Abh4) ...
Cached Biology News:Nanotechnology propels advances in regenerative medicine research 2Regulating the nuclear architecture of the cell 2Regulating the nuclear architecture of the cell 3Regulating the nuclear architecture of the cell 4Regulating the nuclear architecture of the cell 5Brown seaweed contains promising fat fighter, weight reducer 2
(Date:7/25/2014)... Pittsburgh, PA (PRWEB) July 25, 2014 ... annual Call for Topics for Conferee Networking. These two-hour ... similar interests to meet and resolve problems, discuss new ... , The deadline to submit a topic for consideration ... at pittcon.org . The Conferee Networking committee will ...
(Date:7/25/2014)... Biotech Ltd. (Nasdaq: SVA ), a leading provider ... announced that it will release its unaudited financial results for ... on Thursday, August 14, 2014 EDT. The Company will host ... August 15, 2014, at 8:00 a.m. EDT (Friday, August 15, ... Company,s financial results and provide an update on recent corporate ...
(Date:7/24/2014)... 24, 2014  Asterias Biotherapeutics, Inc. (OTCBB: ASTYV), ... of regenerative medicine, announced today that it will ... investors on Tuesday, July 29, 2014, at 4:30 ... include an overview of Asterias, business strategy and ... http://www.ustream.tv/channel/asterias-biotherapeutics at least 15 minutes before ...
(Date:7/24/2014)... Yushan Yan, Distinguished Professor of Engineering at the ... nanomaterials to solve problems in energy engineering, environmental ... focused on zeolites, porous rock with a well-defined, ... size is so precisely decided that zeolites can ... fraction of an angstrom (one-tenth of a nanometer), ...
Breaking Biology Technology:Pittcon 2015 Announces Call for Topics for Conferee Networking Sessions 2Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results 2Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4University of Delaware researcher describes new approach for creating organic zeolites 2
... (TCI), a Los,Angeles-based DNA and genomics research and ... office in the heart of Boston,s legal and,financial ... of,chemical and toxic exposures on human health and ... Consulting, TCI now offers a,range of business, financial, ...
... Watson,Pharmaceuticals, Inc. (NYSE: WPI ), a leading ... will provide an,overview of the Company,s business at ... September 10, 2007 at 3:30 p.m. Eastern,Daylight Time. ... can be accessed on Watson,Pharmaceuticals, Investor Relations Web ...
... INDIANAPOLIS and SOUTH SAN FRANCISCO, Calif., Sept. 4, ... Dow Chemical Company (NYSE: DOW ), and ... Inc. (Nasdaq: EXEL ), announced today,that the ... includes the purchase of selected assets by Dow ...
Cached Biology Technology:Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases 2Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation 2Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation 3
... ZMD.473. Immunogen: Synthetic peptide derived ... mouse junctophilin-2. Specificity: Specific for ... (positive controls: mouse skeletal muscle homogenates ... Applications: Western blotting Immunohistochemistry(froz) ImmunofluorescenceStorage: Store ...
Laminin gamma-2 (G-16)...
ABIN-2 Polyclonal Ab 100 ug rabbit polyclonal antibody. Detects ABIN-2 in human/mouse. Tested in WB....
Syd-2 (cL-19)...
Biology Products: